Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours.

Introduction: Incidence of pancreatic neuroendocrine tumours (pNETs) is on the rise. The only curative treatment is surgical resection in localized or oligo-metastatic disease. However, patients may present with locally advanced or unresectable primary tumours.

Cesium and iodine release from fluoride-based molten salt reactor fuel.

Cesium and iodine, which are formed during a fission process in a nuclear reactor, are considered as major fission products responsible for the environmental burden in case of a nuclear accident. From the safety point of view, it is thus important to understand their release mechanism when overheating of the reactor core occurs. This work presents an experimental investigation of the behaviour of caesium iodide and caesium fluoride in fluoride based molten salt reactor fuel during high temperature events.

Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience.

Purpose: In this study, we describe our experience with peptide receptor radionuclide therapy (PRRT) for initially unresectable liver disease as a two-steps therapeutic strategy, first in neoadjuvant intention before surgery and then later on in case of disease relapse.

Methods: We performed a retrospective evaluation of four cases of unresectable liver metastases of NET of different origins treated with neoadjuvant Lu-177-DotaTATE for conversion into resectability first and as rechallenging treatment after disease relapse.

Results: After treatment with Lu-177-DotaTAE, resectability was reached in three of four cases.

Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?

Background: While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these patients, as well as the use of adjuvant chemotherapy, are still controversial. The aim of the present work is to describe, in a retrospective series of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) G3, the overall survival (OS) rate and risk factors for death after radical surgery. Secondary aims are the description of median recurrence-free survival (RFS) and of the role of adjuvant chemotherapy.